Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1389

A Meta-Analysis of the Prevalence of the Ocular Manifestations in All Inflammatory Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1388

Adalimumab in Patients with Inactive, Non-Infectious Uveitis Requiring Systemic Treatment

9:00AM-11:00AM: Abstract Number: 1392

Azathioprine May be an Effective Steroid Sparing Agent in Patients with Isolated Recurrent Pericarditis

9:00AM-11:00AM: Abstract Number: 1380

Characterization of Lymphocytes Subsets in Peripheral Blood of Untreated IgG4-Related Disease Patients

9:00AM-11:00AM: Abstract Number: 1382

Clinical and Serum IgG4 Characteristics of a Unique British Columbian IgG4-Related Disease Cohort

9:00AM-11:00AM: Abstract Number: 1394

Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 1408

Cogan Syndrome: Differential Response to Biologic Agents and Role of PET-CT in the Increased Diagnosis of Aortitis

9:00AM-11:00AM: Abstract Number: 1384

Comparison of IgG4-Related and Non-IgG4-Related Retroperitoneal Fibrosis; A 12 Year Retrospective Study

9:00AM-11:00AM: Abstract Number: 1404

Death and Infection Rates Appear Reduced in a Modern Cohort of ICU Patients with Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1402

Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis

9:00AM-11:00AM: Abstract Number: 1393

Diagnostic Categorization of Ocular Sarcoidosis Based on the International Criteria Proposed By the First International Workshop on Ocular Sarcoidosis. a Case Series of 11 Spanish Patients

9:00AM-11:00AM: Abstract Number: 1391

Differential Expression of Interferon Gamma in Exudate from Hidradenitis Suppurativa Lesions Compared to Chronic Wounds

9:00AM-11:00AM: Abstract Number: 1385

Efficacy and Tolerance of Rituximab in IgG4-Related Disease: A Retrospective Multicentric Study in 24 Patients

9:00AM-11:00AM: Abstract Number: 1390

Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1379

High Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1400

Hyperferritinemia and Fever in Adults

9:00AM-11:00AM: Abstract Number: 1403

Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports

9:00AM-11:00AM: Abstract Number: 1401

Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?

9:00AM-11:00AM: Abstract Number: 1396

Long Term Outcome of Neurosarcoidosis

9:00AM-11:00AM: Abstract Number: 1386

Malignancy Prevalence Is Increased Among Patients before the Onset of IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1398

Musculoskeletal and Serologic Findings in an Adult Cystic Fibrosis Clinic Population-a Systematic Review and Collation with Disease Status

9:00AM-11:00AM: Abstract Number: 1407

New Clinical Features of Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome

9:00AM-11:00AM: Abstract Number: 1399

Patterns of Arthropathy in Patients with Cystic Fibrosis

9:00AM-11:00AM: Abstract Number: 1395

Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis

9:00AM-11:00AM: Abstract Number: 1409

Subglottic Stenosis: A Unique Inflammatory Disorder

9:00AM-11:00AM: Abstract Number: 1397

Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy

9:00AM-11:00AM: Abstract Number: 1383

T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome

9:00AM-11:00AM: Abstract Number: 1381

The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1406

The Treatment of Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

9:00AM-11:00AM: Abstract Number: 1387

Thoracic Paravertebral Masses and IgG4-Related Disease: Report of 8 Cases and Review of the Literature

9:00AM-11:00AM: Abstract Number: 1405

Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].